1. Home
  2. WIA vs NYXH Comparison

WIA vs NYXH Comparison

Compare WIA & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Inflation-Linked Income Fund

WIA

Western Asset Inflation-Linked Income Fund

SELL

Current Price

$7.64

Market Cap

178.2M

Sector

Finance

ML Signal

SELL

Logo Nyxoah SA

NYXH

Nyxoah SA

SELL

Current Price

$1.11

Market Cap

137.5M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
WIA
NYXH
Founded
2003
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
178.2M
137.5M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
WIA
NYXH
Price
$7.64
$1.11
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $4.20
AVG Volume (30 Days)
56.0K
★ 148.1K
Earning Date
01-01-0001
11-05-2026
Dividend Yield
★ 12.29%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$275.91
Revenue Next Year
N/A
$93.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.45
$1.19
52 Week High
$8.54
$6.00

Technical Indicators

Market Signals
Indicator
WIA
NYXH
Relative Strength Index (RSI) 43.00 31.61
Support Level $7.45 N/A
Resistance Level $8.21 $1.69
Average True Range (ATR) 0.07 0.06
MACD 0.01 -0.02
Stochastic Oscillator 78.26 2.50

Price Performance

Historical Comparison
WIA
NYXH

About WIA Western Asset Inflation-Linked Income Fund

Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: